Market Overview

Why Immunic's Stock Is Trading Higher Today


Immunic (NASDAQ: IMUX) shares are trading higher on Friday after SVB Leerink initiated coverage on the stock with an Outperform rating and announced a price target of $45 per share.

Immunic is a clinical stage biopharmaceutical company developing a pipeline of selective oral immunology therapies aimed at treating chronic inflammatory and autoimmune diseases, including ulcerative colitis, Crohn's disease, relapsing remitting multiple sclerosis, and psoriasis. The company is developing three small molecule products, IMU-838 is a selective immune modulator that inhibits the intracellular metabolism of activated immune cells by blocking the enzyme DHODH, IMU-935 is an inverse agonist of RORγt and IMU-856 targets the restoration of the intestinal barrier function.

Immunic shares traded up 8.43% to $20.46 on Friday. The stock has a 52-week high of $23.39 and a 52-week low of $4.19.

Latest Ratings for IMUX

Oct 2020SVB LeerinkInitiates Coverage OnOutperform
Aug 2020Piper SandlerInitiates Coverage OnOverweight
Aug 2020HC Wainwright & Co.MaintainsBuy

View More Analyst Ratings for IMUX
View the Latest Analyst Ratings


Related Articles (IMUX)

View Comments and Join the Discussion!

Posted-In: why it's movingInitiation Analyst Ratings

Latest Ratings

WWEEvercore ISI GroupUpgrades
INTB of A SecuritiesUpgrades40.0
BLDPBMO CapitalInitiates Coverage On39.0
SSYSStifelInitiates Coverage On40.0
CMGGoldman SachsInitiates Coverage On1,650.0
View the Latest Analytics Ratings
Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at